Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
about
Role of HER2 in NSCLCEGFR mutations as a prognostic and predictive marker in non-small-cell lung cancerMolecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agentsCorrelations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.Relationship between EGFR expression, copy number and mutation in lung adenocarcinomasA multi-analyte serum test for the detection of non-small cell lung cancer.Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cellsGenetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.Assessment of ERBB2 and EGFR gene amplification and protein expression in gastric carcinoma by immunohistochemistry and fluorescence in situ hybridization.Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.Selective targeting of antibody conjugated multifunctional nanoclusters (nanoroses) to epidermal growth factor receptors in cancer cellsHigh predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC)Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluationTreatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib.Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer.Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.Polymorphisms in intron 1 of the EGFR gene in non-small cell lung cancer patients.Epidermal growth factor receptor inhibition and non-small cell lung cancer.Imaging characteristics of stage I non-small cell lung cancer on CT and FDG-PET: relationship with epidermal growth factor receptor protein expression status and survival.Gene Expression of the EGF System-a Prognostic Model in Non-Small Cell Lung Cancer Patients Without Activating EGFR Mutations.HER2-siRNA delivered by EGFR-specific single chain antibody inhibits NSCLC cell proliferation and tumor growth.The effect of HER2 expression on cisplatin-based chemotherapy in advanced non-small cell lung cancer patients.Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR familyLapatinib: new opportunities for management of breast cancer.Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: overcoming resistance to reversible EGFR inhibitors.Molecular predictors of prognosis in lung cancer.Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.Evaluation of current methods to detect the mutations of epidermal growth factor receptor in non-small cell lung cancer patientsEGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study.Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate.Expression levels of some antioxidant and epidermal growth factor receptor genes in patients with early-stage non-small cell lung cancer.The relationship between EGFR gain and VHL loss in lung adenocarcinoma and poor patient survival.Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC).Frequent overexpression of ErbB--receptor family members in brain metastases of non-small cell lung cancer patients.Cancer cell identification by bi-color ZnO and TiO2 nanowires.Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer.
P2860
Q26781683-5A460B5E-C2B5-4A2C-8329-2D02A97B550AQ26852507-463589FA-7F4D-4CEA-A1B0-735BD2B813C9Q28304646-7537BEBB-04FA-4E17-AC71-43EDFBB7DCADQ33290653-88028C3E-AD8F-4F07-9891-9D2891FB935AQ33390513-071299F3-40C8-4955-8D8F-04B9157D83A5Q33634703-0FB61C40-AFD2-4389-AC17-DC1CC322339DQ34255948-1E129B0B-A900-445A-8700-82F750C5426CQ34768400-477AEA5C-671D-4190-B119-1620F9D2FC96Q35072797-63608F7B-A9BF-49E9-AF2E-EFD45CD71238Q35122508-4A006566-1D47-4987-B4D3-61D9CB5D27BEQ35588760-1F6700E0-8047-447E-9268-E8EBC0522E80Q35622986-E1A97111-3650-4387-B920-32E477A65507Q35769805-FBBF9288-EF31-4CCC-90F0-6EAE52867366Q35770249-0D5BDFF5-533C-4BF8-93CA-0A427B752C18Q35875986-33226A28-4EE2-4D6D-A2C2-5702A4BC0683Q36302860-61D32F59-3FB5-4906-82F1-ABF5E64916BCQ36311791-9CA4FCE2-324E-40F4-A308-18741BFF1EDCQ36385082-9EF1C99C-F167-43FA-829A-033E5944D6AAQ36504349-BAADF8A9-B15E-4C53-AB7A-AEB9072AA47EQ36662662-E13843EA-67F6-4CCD-BCAC-622C458550D9Q37221902-38C58AD5-3D53-4412-B29B-9863815E8ED4Q37269081-A93FF24A-4399-4096-83B4-0A7303FFB939Q37278752-9FEE86C0-6BA7-4A35-9DA9-79FB362EE8ACQ37316604-C0FE91AC-5A7E-458E-9EEC-F616A911AB45Q37355729-A5DA3391-2EC9-4C78-9FE8-628F8AB77E68Q37579647-9207A942-3C2B-4CE1-9572-82AC7CE8B509Q37667783-535E5B69-FFCE-468E-83AB-74EC0A045CD8Q37715991-8CCC77CC-8B98-406A-AF79-3263FEBF443AQ37913090-84ADAF5F-10D5-417B-AB54-2291D757FA5EQ38008698-24941098-8BB6-4B25-AA63-9B4A18E20186Q40694780-399D3BD3-301D-4D4F-9C65-1F1B4600B1F5Q41973777-18B8E2E0-1C0A-4891-A3F5-6B6E8CD3E9AEQ42485639-6B01DB74-84F6-4EA3-88EA-B61205A70175Q42506146-ADE2B651-9D1D-4AFB-962B-9D33F3624D1EQ42672586-E1B62FF5-02FB-4182-A990-2FC291453541Q44587904-6261F2CB-639B-41CB-A793-7A831BD8D0FEQ45210729-716A8B38-708D-4B1E-B280-E086F2159F1FQ45721936-E209429F-6D03-48C9-B64F-EE1195C6F073Q50235535-8F863A36-C19C-4CE5-84F9-E289AA652DD3Q54326192-C1F9D572-F9DC-4664-BAD5-A540B0FB8775
P2860
Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Synchronous overexpression of ...... I non-small cell lung cancer.
@en
Synchronous overexpression of ...... I non-small cell lung cancer.
@nl
type
label
Synchronous overexpression of ...... I non-small cell lung cancer.
@en
Synchronous overexpression of ...... I non-small cell lung cancer.
@nl
prefLabel
Synchronous overexpression of ...... I non-small cell lung cancer.
@en
Synchronous overexpression of ...... I non-small cell lung cancer.
@nl
P2093
P50
P1476
Synchronous overexpression of ...... I non-small cell lung cancer.
@en
P2093
Arlene M Correa
Corazon D Bucana
Isaiah J Fidler
Joe B Putnam
Michael Gilcrease
Michael S O'Reilly
Takeshi Isobe
Waun K Hong
P304
P356
10.1158/1078-0432.CCR-0373-3
P407
P433
P577
2004-01-01T00:00:00Z